Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 13 February 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Integrating budesonide-MMX into treatment algorithms for ulcerative colitis

A study in the latest Alimentary Pharmacology & Therapeutics reviews integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.

News image

5-Aminosalicylates (5-ASA) are first-line treatment for mild–moderately active ulcerative colitis.

When 5-ASAs fail, systemic corticosteroids have been the standard next step.

Due to the significant side effect profile of systemic corticosteroids, alternative options in the treatment algorithm after 5-ASA failures are needed.

Budesonide-Multi-Matrix System (MMX) is a novel oral formulation of budesonide that uses colonic release MMX technology to extend release of the drug to the colon.

Now that budesonide-MMX has been approved for use in some countries, and pending in others there is a need to understand its position in the treatment algorithm for ulcerative colitis.

Dr Danese and colleagues from Italy reviewed the available literature for budesonide-MMX and incorporate it into the treatment algorithm for mild–moderate ulcerative colitis.

Safety data are reassuring, including those for steroid-related side effects
Alimentary Pharmacology & Therapeutics

The team reviewed the available efficacy and safety literature regarding budesonide-MMX, and compared to 5-ASAs and systemic corticosteroids.

In two large studies referred to as CORE (Colonic Release Budesonide trial), budesonide-MMX 9 mg daily was significantly more effective in achieving a combined end point of clinical and endoscopic remission than placebo in patients with mild–moderately active ulcerative colitis.

The researchers report that safety data are reassuring, with no clinically relevant differences between budesonide-MMX and placebo, including steroid-related side effects.

Dr Danese's team comments, "Budesonide-MMX 9 mg daily is an effective and safe treatment for induction in patients with mild–moderately active ulcerative colitis."

"At the current time, it should be considered in patients after 5-ASA failure and before systemic corticosteroids."

"Data are still needed to understand its role and dose beyond 8 weeks, and if it should be considered first line before 5-ASAs."

Aliment Pharmacol Ther 2014: 39(10): 1095–1103
29 April 2014

Go to top of page Email this page Email this page to a colleague

 12 February 2016 
Colorectal cancer after negative signoidoscopy
 12 February 2016 
Genetic factors and response to glucocorticoids in IBD
 12 February 2016 
Tobacco smoking and the natural history of Crohn’s
 11 February 2016 
Colorectal surgery training
 11 February 2016 
Liver disease unique to pregnancy
 11 February 2016 
Serous cystic neoplasm 
 10 February 2016 
NAFLD in Veterans in the USA
 10 February 2016 
Rectosigmoidoscopy vs colonoscopy in ulcerative colitis
 10 February 2016 
Liver cancer and primary biliary cirrhosis
 09 February 2016 
Bowel preparation for colonoscopy screening
 09 February 2016 
Eosinophilic esophagitis and parental allergies
 09 February 2016 
Cancer-specific prognosis in octogenarians with colorectal cancer
 08 February 2016 
Cancelled colonoscopy appointments
 08 February 2016 
Cognitive function in Crohn's disease
 08 February 2016 
Immunity in the human gut
 05 February 2016 
Treatment for ileal pouch-anal anastomosis for Crohn’s colitis
 05 February 2016 
Helicobacter cinaedi bacteremia
 05 February 2016 
Methotrexate and remission in ulcerative colitis
 04 February 2016 
Diabetes and liver cancer
 04 February 2016 
Colorectal cancer screening
 04 February 2016 
H. pylori and coronary heart disease 
 03 February 2016 
Acute diverticulitis and IBS 
 03 February 2016 
Microbiota of the colonic mucosa and chronic constipation
 03 February 2016 
Guidelines for chronic pancreatitis
 02 February 2016 
Ramosetron and IBS-diarrhea
 02 February 2016 
IBD emergency department visits
 02 February 2016 
Probiotics for H. pylori management
 01 February 2016 
Managing HBV in pregnancy
 01 February 2016 
Depressive symptoms in IBD 
 01 February 2016 
Obesity and hepatocellular carcinoma risk
 29 January 2016 
Colorectal cancer after colonoscopy
 29 January 2016 
Acute diverticulitis in immunosuppressed patients
 29 January 2016 
Vitamin D and colorectal cancer risk
 28 January 2016 
Tissue anti-TNF drug levels and IBD
 28 January 2016 
First line treatment of H. pylori infection
 28 January 2016 
Tetracycline for rosacea increases the risk of IBD
 27 January 2016 
Steroids in children with Crohn's
 27 January 2016 
Self-management IBS program 
 27 January 2016 
Human gut microbiome in IBD 
 26 January 2016 
Smoking and symptomatic diverticular disease
 26 January 2016 
Step-down therapy in PPI-responsive esophageal eosinophilia 
 26 January 2016 
Diet and IBD risk
 25 January 2016 
IBD monitoring using smartphones
 25 January 2016 
Self-management IBS program
 25 January 2016 
Colorectal cancer after a negative screening sigmoidoscopy
 22 January 2016 
Length of Barrett's and cancer
 22 January 2016 
Psychosocial interventions and alcohol abstinence in chronic liver disease
 22 January 2016 
Helicobacter pylori antibiotic resistance
 21 January 2016 
Increasing adenoma detection rate during colonoscope withdrawal
 21 January 2016 
Microscopic colitis current concepts
 21 January 2016 
Statins as a management strategy for constipation 
 20 January 2016 
Health status after bariatric surgery
 20 January 2016 
Hep E infection in West Africa
 20 January 2016 
Preventing endoscopic bacterial transmission
 19 January 2016 
PPIs and phlebotomy in hereditary hemochromatosis
 19 January 2016 
Predicting liver cirrhosis in Hep C
 19 January 2016 
Frozen vs fresh fecal microbiota transplantation
 18 January 2016 
Hospitalization for diverticulitis in the USA
 18 January 2016 
H. pylori and gastric cancer across Europe
 18 January 2016 
Enteral nutrition in children with Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us